
OCV
Description
OCV Partners is a Los Angeles-based venture capital firm established in 2014, specializing in early-stage technology investments. The firm primarily targets Seed and Series A rounds, positioning itself as a key partner for nascent companies with disruptive potential. OCV's investment thesis centers on backing exceptional founders who are building innovative businesses poised to redefine their respective markets.
The firm maintains a focused investment strategy, concentrating its capital on specific high-growth technology sectors. These include enterprise software, cybersecurity, fintech, and digital health. OCV seeks out companies that leverage cutting-edge technology to solve complex problems and create significant value. Their approach often involves leading or co-leading investment rounds, indicating a hands-on and strategic involvement with their portfolio companies.
OCV Partners typically deploys initial investments ranging from $2 million to $10 million, providing substantial early-stage capital to fuel growth and product development. This range allows them to support a diverse set of companies from their initial commercialization efforts through significant scaling. For instance, their OCV Fund II successfully closed at $140 million in 2021, underscoring their capacity to deploy meaningful capital into promising ventures. Beyond capital, OCV emphasizes providing strategic guidance and leveraging their network to help portfolio companies navigate challenges and accelerate their market penetration.
Investor Profile
OCV has backed more than 21 startups, with 3 new investments in the last 12 months alone. The firm has led 6 rounds, about 29% of its total and boasts 4 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series A, Series C, Series B rounds (top funding stages).
- Majority of deals are located in United States, Israel.
- Strong thematic focus on Biotechnology, Health Care, Artificial Intelligence (AI).
- Typical check size: $2M – $10M.
Stage Focus
- Series A (33%)
- Series C (29%)
- Series B (24%)
- Series D (10%)
- Series Unknown (5%)
Country Focus
- United States (86%)
- Israel (14%)
Industry Focus
- Biotechnology
- Health Care
- Artificial Intelligence (Ai)
- Software
- Medical
- Enterprise Software
- Nutrition
- Wellness
- Clinical Trials
- Insurtech
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.